article
US perspective on the impact of Brexit on the pharmaceutical sector
As the UK prepares to withdraw from the EU on 29th March 2019 at 23:00, this article delivers a US perspective on what Brexit is likely to mean for pharmaceutical companies.
List view / Grid view
Big Pharma
news
Russian Institute for Drugs and Good Practices unveils new data guide
Improving data integrity is the aim of a new guide published by the Russian State Institute for Drugs and Good Practices in collaboration with consultancy PQE Group...
webinar
Understanding current CFR 21.11 and data integrity requirements
8 August 2018 | By SUEZ
The US FDA and European Commission have defined regulations relating to the submission of electronic records in lieu of paper documents, for submission, inspection, and archiving purposes. When ageing analytical equipment is to be replaced 21CFR Part 11 and EU Annex 11 are also topics of discussion. Common questions from…
news
Public trust in use of Big Data for health science ‘is vital’: researchers
Maintaining public confidence in the use of Big Data for health research is essential, according to international researchers.
news
Aimovig approved by EU for migraine prevention
Researchers found that more than one quarter (26 per cent) of patients taking Aimovig 70mg were migraine free after month 15...
article
Non-mutagenic impurities: more guidance needed on safety-based limits
More guidance is needed on the appropriate control of non-mutagenic impurities during clinical development, explains Dave P Elder, JPAG Member and pharmaceutical industry consultant, in this audio interview.
news
RSSL appoints new Head of Training
Reading Scientific Services Ltd (RSSL) has appointed Katarzyna Szymaniec to lead its accredited pharmaceutical training business and align its strategic development with the diverse needs of professionals working within the sector...
article
Guide to Analytical Equipment
In this edition, two leading analytical equipment suppliers explain how their products meet current industry requirements.
news
EMA’s building approval process in Amsterdam initiated
New permanent building to be completed by 15 November 2019...
article
Boehringer Ingelheim: Achievements to be proud of
Allan Hillgrove, Member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit at Boehringer Ingelheim, tells EPR about some of his company’s achievements that he is most proud of, and describes how it will face the digital challenge...
news
UK Life Sciences firms struggle in post-Brexit war for EU talent
Following the Brexit vote, the UK is already seeing problems in filling senior positions at life sciences companies, with their average “slate” of candidates falling from around 40% non-UK nationals to just 15% non-UK candidates on average...
article
Pfizer: Concentrating on core areas to improve lives
For Pfizer, putting patients first guides its actions, informs its strategic decisions and unifies colleagues in every region and function across the company. Beatriz Faro, Regional President, Internal Medicine, International Developed Markets at Pfizer, explains how the company’s philosophy is taking the business forward...
article
Pharma patent challenges for 2018
Christof Hohne, partner at patent law firm EIP, discusses second medical use claims and compulsory licences...
article
21st Anniversary Supplement
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
article
The impact of Brexit on life sciences
On 30 March 2019 the UK is set to leave the European Union (EU), a process that has become popularly known as Brexit. One little talked-about aspect of this move in the mainstream media is the impact it will have on the British life science community. Researchers and industry leaders…
